NeuroShield granted US patent
Monarch Bioimplants has been granted a US patent (# 10,328,096) to protect its advanced chitosan-based technology for use in the prevention and/or treatment of impotence in patients undergoing radical prostatectomy. This milestone is an important pre-requisite for the launch of the company's flagship product NeuroShield™ in the US market which is planned in October 2019.
Following the recent FDA clearance of NeuroShield™ in the US, its protection by a US patent allows to enter this large medical device market with a sustainable commercialization strategy. Moreover, the company is continuing to expand its patent portfolio, and a new patent application protecting innovative structures to further enhance the potency recovery has recently been submitted.